SAS macro programme for Bang's Blinding Index to assess and visualise the success of blinding in randomised controlled trials.

Autor:	Qin Z; Peking University Clinical Research Institute, Beijing, China., Yu Y; Peking University Clinical Research Institute, Beijing, China., Gu H; Department of Neurology and China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China., Shi D; Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China., Wang Z; Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China., Wu J; Department of Acupuncture and Neurology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China., Furukawa T; Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine and School of Public Health, Kyoto, Japan., Wu Y; Peking University Clinical Research Institute, Beijing, China.
Jazyk:	angličtina
Zdroj:	General psychiatry [Gen Psychiatr] 2024 Dec 07; Vol. 37 (6), pp. e101578. Date of Electronic Publication: 2024 Dec 07 (Print Publication: 2024).
DOI:	10.1136/gpsych-2024-101578
Abstrakt:	This paper aims to present a Statistical Analysis Software (SAS) macro %BBIplus, offering estimation and visualisation methods for the Bang's Blinding Index (BBI) for randomised controlled trials (RCTs) with various designs. We developed the SAS macro programme %BBIplus to facilitate the implementation of BBI. This user-friendly programme allows for easy and rapid estimation and visualisation of BBI across different scenarios, including pairwise comparison RCTs with two arms, double-dummy design RCTs with three arms and factorial design RCTs with four arms. The programme requires no pre-existing data set, and users only need to input the number of individuals of correct, uncertain or wrong guesses in each intervention or control group. We illustrate the functionality of %BBIplus using blinding assessment data from three previously published RCTs: BBR (adjunctive berberine reduces antipsychotic-associated weight gain and metabolic syndrome in patients with schizophrenia: a randomised controlled trial), SELECT-TDCS (the sertraline versus electrical current therapy for treating depression clinical study: results from a factorial, randomised controlled trial) and ELECT-TDCS (trial of electrical direct-current therapy versus escitalopram for depression) studies. The programme estimates the BBI for each arm, providing point estimates, 95% CI and associated p values. Additionally, %BBIplus can visualise the estimations through forest plots and make the judgement for the success of blinding easily and rapidly. This tool caters to the needs of clinical trial investigators, offering a comprehensive solution for estimating and visualising the blinding index under various RCT designs. Competing Interests: None declared. (Copyright © Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu